First patient dosed in phase 1/2 trial of topical anti-VEGF drop from PanOptica

PanOptica has begun a phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily anti-VEGF topical eye drop formulation, the company announced in a press release.
The masked study is evaluating the new suspension formulation as monotherapy in 60 patients newly diagnosed with neovascular age-related macular degeneration. Three dose strengths will be studied for up to 3 months at sites in the United States and Europe, the release said.
“This phase 1/2 trial builds on research completed to date and advances PAN-90806 as a potentially safe and effective topical eye drop (Read more...)

Full Story →